Title: Clinical Observation of Simvastatin Combined with Atorvastatin Calcium in the Treatment of Mixed Hyperlipidemia
Abstract:OBJECTIVE:To observe the clinical efficacy and safety of atorvastatin calcium combined with simvastatin in the treatment of mixed hyperlipidemia. METHODS:Totally 78 patients with mixed hyperlipidemia ...OBJECTIVE:To observe the clinical efficacy and safety of atorvastatin calcium combined with simvastatin in the treatment of mixed hyperlipidemia. METHODS:Totally 78 patients with mixed hyperlipidemia were randomly divided into control group and observation group. Two groups of patients were given routine treatment of hypoglycemic and anti-hypertension and stopping other lipid-lowering drugs. Based on it,patients in control group were given Atorvastatin calcium tablets 20 mg;it was taken at bed-time every night,qd. Patients in observation group were given Simvastatin tablets 20 mg based on the treatment of control group;it was orally taken at bed-time every night,qd. The course of both was 8 weeks. The clinical data was observed,including the clinical efficacy,qualified rate of lipid,TC,TG,LDL-C,HDL-C and adverse reactions(ADR)occurrence before and after treatment. RESULTS:The total effective rate and control rate of lipid in observation group were significantly higher than control group,with significant difference(P0.05). After treatment,the TG,TC and LDL-C in 2 groups were significantly lower than before and observation group was lower than control group;HDL-C was significantly higher than before and observation group was higher than control group(P0.05). There was no significant difference in the incidence of adverse reaction(P0.05). CONCLUSIONS:Atorvastatin calcium combined with simvastatin have more significant efficacy than only atorvastatin calcium in the treatment of mixed hyperlipidemia. They have similar safety.Read More
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot